Five Prime Therapeutics Inc (FPRX) 14.78 $FPRX
Five Prime Therapeutics to Present Data From Healthy Volunteer Cohorts in Phase 1 Trial of FPA008 at the 2014 ACR/ARHP Annual Scientific Meeting
GlobeNewswire - 2 hrs 1 min ago
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced that it will present results from the healthy volunteer cohorts in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF-1R). The results will be featured in a poster presentation titled "A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF-1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results" at the 2014 American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting. The meeting is being held November 14-19, 2014 in Boston, Massachusetts, and the poster presentation is scheduled to take place on Monday, November 17 from 9:00 am to 11:00 am, with the poster viewable from 8:30 am to 4:00 pm. (Presentation Number 1493). The abstracts are available in the online meeting supplement: http://www.acrannualmeeting.org/wp-content/up...ement2.pdf.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics' (FPRX) CEO Dr. Rusty Williams on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 6:39PM CST
FPRX: 14.78 (+0.24)
Five Prime Therapeutics posts 3Q loss
Automated Insights - Mon Nov 10, 4:33PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Monday reported a loss of $7.1 million, or 33 cents per share, in its third quarter.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:33PM CST
FPRX: 14.78 (+0.24)
Five Prime Therapeutics Announces Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:20PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ending September 30, 2014.
BMY: 57.80 (-0.81), FPRX: 14.78 (+0.24)
Five Prime Therapeutics Announces Presentation at the 2014 Society for Immunotherapy of Cancer Annual Meeting
GlobeNewswire - Wed Nov 05, 3:37PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced that it will present a poster describing the use of the company's protein screening platform to identify unique cancer immunotherapy targets on November 7 and 8 at the Society for Immunotherapy of Cancer (SITC) 29 Annual Meeting. The meeting is being held November 6-9, 2014, in National Harbor, Maryland.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics to Announce Third Quarter 2014 Financial Results and Host Conference Call on November 10
GlobeNewswire - Mon Nov 03, 5:30PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its third quarter 2014 financial results on Monday, November 10, 2014, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Monday, November 10, 2014, at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 14.78 (+0.24)
5 Stocks Poised for Big Breakouts
at The Street - Mon Oct 27, 8:32AM CDT
These stocks look ready to break out and trade higher from current levels.
ANIP: 51.47 (-1.23), KTOS: 5.37 (+0.03), BLOX: 16.53 (-0.29), CSLT: 11.83 (-0.32), FPRX: 14.78 (+0.24)
Five Prime expands research deal with Glaxo
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 3:50PM CDT
GSK: 45.66 (+0.04), FPRX: 14.78 (+0.24)
Five Prime Therapeutics Announces Expansion of Respiratory Disease Research Collaboration and License Agreement With GSK
GlobeNewswire - Thu Oct 23, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), today announced an expansion of its respiratory disease research collaboration with GSK that was established in 2012 to identify first-in-class agents and new mechanisms for the treatment of refractory asthma and chronic obstructive pulmonary disease (COPD). The scope of the collaboration was increased in April 2014 to include two additional respiratory disease discovery programs for a six-month evaluation period, and GSK has now committed to continue these two discovery programs for an additional 18 months.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics (FPRX) Initiated As a Sell
at The Street - Wed Oct 22, 8:13AM CDT
Five Prime Therapeutics (FPRX) has been initiated by TheStreet Ratings as a Sell with a ratings score of D.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics Appoints Bill Ringo to Its Board of Directors
GlobeNewswire - Thu Oct 02, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Bill Ringo, a strategic advisor at Sofinnova Ventures, to the company's Board of Directors. The addition of Mr. Ringo increases the number of directors from eight to nine.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics elects Dr. Robert Sikorski as VP of Global Clinical Development
M2 - Thu Sep 18, 5:41AM CDT
Biotechnology company Five Prime Therapeutics (FPRX) disclosed on Wednesday the election of Dr. Robert Sikorski, M.D., Ph.D., as vice president of its Global Clinical Development.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:00PM CDT
Five Prime Therapeutics, Inc. (FPRX) will get $1.5 million with Glaxo exercising its option under their 2010 agreement.
CBM: 23.36 (-0.66), BMY: 57.80 (-0.81), GSK: 45.66 (+0.04), FPRX: 14.78 (+0.24)
Five Prime Therapeutics Appoints Dr. Robert Sikorski as Vice President of Global Clinical Development
GlobeNewswire - Wed Sep 17, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Robert Sikorski, M.D., Ph.D., as Vice President of Global Clinical Development. Dr. Sikorski will oversee the global clinical development activities for Five Prime's product candidates.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline for a Commercial License to a Novel Muscle Disease Target
GlobeNewswire - Mon Sep 15, 3:39PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced today that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target that Five Prime discovered using its proprietary library of human extracellular proteins and target screening and discovery capabilities.
GSK: 45.66 (+0.04), FPRX: 14.78 (+0.24)
Five Prime Therapeutics to Present at Morgan Stanley 2014 Global Healthcare Conference
GlobeNewswire - Wed Sep 03, 12:29PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Morgan Stanley 2014 Global Healthcare Conference on Tuesday, September 9 at 5:15 PM Eastern Time. The conference will take place at the Grand Hyatt in New York City.
FPRX: 14.78 (+0.24), MS: 35.84 (-0.13)
How Five Prime Therapeutics (FPRX) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:33AM CDT
Five Prime Therapeutics (FPRX) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 72 out of more than 250 industries.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 7:51AM CDT
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as its shares rose over 10% on the day.
CBM: 23.36 (-0.66), GILD: 104.20 (-2.70), FPRX: 14.78 (+0.24)
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.47 (-0.03), NWBO: 5.92 (+0.04), CVM: 0.61 (-0.03), CLDX: 14.26 (-0.55), INCY: 71.21 (-0.66), AZN: 74.53 (+0.27), MRK: 59.54 (+0.23), DNDN: 0.13 (-0.03), NLNK: 31.00 (-1.39), PPHM: 1.44 (-0.03), BMY: 57.80 (-0.81), FPRX: 14.78 (+0.24)
Five Prime Therapeutics to Present Data From Healthy Volunteer Cohorts in Phase 1 Trial of FPA008 at the 2014 ACR/ARHP Annual Scientific Meeting
GlobeNewswire - 2 hrs 1 min ago
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced that it will present results from the healthy volunteer cohorts in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF-1R). The results will be featured in a poster presentation titled "A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF-1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results" at the 2014 American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting. The meeting is being held November 14-19, 2014 in Boston, Massachusetts, and the poster presentation is scheduled to take place on Monday, November 17 from 9:00 am to 11:00 am, with the poster viewable from 8:30 am to 4:00 pm. (Presentation Number 1493). The abstracts are available in the online meeting supplement: http://www.acrannualmeeting.org/wp-content/up...ement2.pdf.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics' (FPRX) CEO Dr. Rusty Williams on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 6:39PM CST
FPRX: 14.78 (+0.24)
Five Prime Therapeutics posts 3Q loss
Automated Insights - Mon Nov 10, 4:33PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Monday reported a loss of $7.1 million, or 33 cents per share, in its third quarter.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:33PM CST
FPRX: 14.78 (+0.24)
Five Prime Therapeutics Announces Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:20PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ending September 30, 2014.
BMY: 57.80 (-0.81), FPRX: 14.78 (+0.24)
Five Prime Therapeutics Announces Presentation at the 2014 Society for Immunotherapy of Cancer Annual Meeting
GlobeNewswire - Wed Nov 05, 3:37PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced that it will present a poster describing the use of the company's protein screening platform to identify unique cancer immunotherapy targets on November 7 and 8 at the Society for Immunotherapy of Cancer (SITC) 29 Annual Meeting. The meeting is being held November 6-9, 2014, in National Harbor, Maryland.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics to Announce Third Quarter 2014 Financial Results and Host Conference Call on November 10
GlobeNewswire - Mon Nov 03, 5:30PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its third quarter 2014 financial results on Monday, November 10, 2014, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Monday, November 10, 2014, at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 14.78 (+0.24)
5 Stocks Poised for Big Breakouts
at The Street - Mon Oct 27, 8:32AM CDT
These stocks look ready to break out and trade higher from current levels.
ANIP: 51.47 (-1.23), KTOS: 5.37 (+0.03), BLOX: 16.53 (-0.29), CSLT: 11.83 (-0.32), FPRX: 14.78 (+0.24)
Five Prime expands research deal with Glaxo
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 3:50PM CDT
GSK: 45.66 (+0.04), FPRX: 14.78 (+0.24)
Five Prime Therapeutics Announces Expansion of Respiratory Disease Research Collaboration and License Agreement With GSK
GlobeNewswire - Thu Oct 23, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), today announced an expansion of its respiratory disease research collaboration with GSK that was established in 2012 to identify first-in-class agents and new mechanisms for the treatment of refractory asthma and chronic obstructive pulmonary disease (COPD). The scope of the collaboration was increased in April 2014 to include two additional respiratory disease discovery programs for a six-month evaluation period, and GSK has now committed to continue these two discovery programs for an additional 18 months.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics (FPRX) Initiated As a Sell
at The Street - Wed Oct 22, 8:13AM CDT
Five Prime Therapeutics (FPRX) has been initiated by TheStreet Ratings as a Sell with a ratings score of D.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics Appoints Bill Ringo to Its Board of Directors
GlobeNewswire - Thu Oct 02, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Bill Ringo, a strategic advisor at Sofinnova Ventures, to the company's Board of Directors. The addition of Mr. Ringo increases the number of directors from eight to nine.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics elects Dr. Robert Sikorski as VP of Global Clinical Development
M2 - Thu Sep 18, 5:41AM CDT
Biotechnology company Five Prime Therapeutics (FPRX) disclosed on Wednesday the election of Dr. Robert Sikorski, M.D., Ph.D., as vice president of its Global Clinical Development.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:00PM CDT
Five Prime Therapeutics, Inc. (FPRX) will get $1.5 million with Glaxo exercising its option under their 2010 agreement.
CBM: 23.36 (-0.66), BMY: 57.80 (-0.81), GSK: 45.66 (+0.04), FPRX: 14.78 (+0.24)
Five Prime Therapeutics Appoints Dr. Robert Sikorski as Vice President of Global Clinical Development
GlobeNewswire - Wed Sep 17, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Robert Sikorski, M.D., Ph.D., as Vice President of Global Clinical Development. Dr. Sikorski will oversee the global clinical development activities for Five Prime's product candidates.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline for a Commercial License to a Novel Muscle Disease Target
GlobeNewswire - Mon Sep 15, 3:39PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced today that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target that Five Prime discovered using its proprietary library of human extracellular proteins and target screening and discovery capabilities.
GSK: 45.66 (+0.04), FPRX: 14.78 (+0.24)
Five Prime Therapeutics to Present at Morgan Stanley 2014 Global Healthcare Conference
GlobeNewswire - Wed Sep 03, 12:29PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Morgan Stanley 2014 Global Healthcare Conference on Tuesday, September 9 at 5:15 PM Eastern Time. The conference will take place at the Grand Hyatt in New York City.
FPRX: 14.78 (+0.24), MS: 35.84 (-0.13)
How Five Prime Therapeutics (FPRX) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:33AM CDT
Five Prime Therapeutics (FPRX) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 72 out of more than 250 industries.
FPRX: 14.78 (+0.24)
Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 7:51AM CDT
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as its shares rose over 10% on the day.
CBM: 23.36 (-0.66), GILD: 104.20 (-2.70), FPRX: 14.78 (+0.24)
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.47 (-0.03), NWBO: 5.92 (+0.04), CVM: 0.61 (-0.03), CLDX: 14.26 (-0.55), INCY: 71.21 (-0.66), AZN: 74.53 (+0.27), MRK: 59.54 (+0.23), DNDN: 0.13 (-0.03), NLNK: 31.00 (-1.39), PPHM: 1.44 (-0.03), BMY: 57.80 (-0.81), FPRX: 14.78 (+0.24)
